Effects of Concurrent Strength and Aerobic Exercise Training on Cognitive Health in Adults With Physiological or Neurocognitive Disorders: Systematic Review With Meta-analysis of Randomized Controlled Trials.

Sports HealthJun 25, 2026 (epub)

Mingyang Zhang, Ruixiang Yan, Lijie Lou et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis of randomized controlled trials assessed concurrent strength and aerobic exercise training (CET) and global cognition in middle-aged and older adults with physiological or neurocognitive disorders. Across 22 trials involving 3463 participants, CET was associated with better global cognitive function than control conditions (SMD = 0.34; 95% CI, 0.18 to 0.50; P < 0.001). Subgroup analyses also found significant improvements among participants with physiological disorders and those with neurocognitive disorders. The overall result showed substantial heterogeneity (I 2 = 67%), so the pooled estimate represents varied trial findings.

Key findings

  • Across 22 RCTs and 3463 participants, CET improved global cognition versus controls (SMD = 0.34; 95% CI, 0.18 to 0.50; P < 0.001; I 2 = 67%).
  • In physiological disorders, CET was associated with improved cognition (SMD = 0.29; 95% CI, 0.09 to 0.49; P < 0.01).
  • In neurocognitive disorders, CET was associated with improved cognition (SMD = 0.37; 95% CI, 0.14 to 0.55; P < 0.01).
  • No publication bias was detected by Egger's test (P = 0.62).

Why it matters

Cognitive impairment occurs across a range of physiological and neurocognitive conditions. The pooled findings suggest that combining strength and aerobic exercise may support global cognition in these populations, extending the relevance of exercise beyond physical outcomes. However, the substantial heterogeneity indicates that effects varied across trials, and the results do not establish the benefit for every condition or individual.

What to keep in mind

The pooled result showed substantial heterogeneity (I 2 = 67%), indicating variation across trial findings.

Source

Published in Sports Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.